LRAT

Lecithin retinol acyltransferase · O95237 · LRAT on Sugi Atlas →

2,804 patent compounds predicted against LRAT, 2,256 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

Compound	Confidence	Supporting neighbours
Neamine (SCHEMBL219578)	1.00	2/20
Neamine (SCHEMBL2736468)	1.00	2/20
Neamine (SCHEMBL11590075)	1.00	2/20
Neamine (SCHEMBL12591591)	1.00	2/20
Neamine (SCHEMBL1762107)	0.97	2/20
Neamine (SCHEMBL3669932)	0.97	2/20
Neamine (SCHEMBL6446250)	0.97	2/20
Ribostamycin (SCHEMBL48819)	0.88	2/20
Ribostamycin (SCHEMBL48820)	0.88	2/20
Ribostamycin (SCHEMBL1649929)	0.88	2/20
Ribostamycin (SCHEMBL4318426)	0.88	2/20
SCHEMBL12168040	0.88	2/20
Ribostamycin (SCHEMBL7536243)	0.86	2/20
Framycetin (SCHEMBL3037)	0.84	2/20
Neamine (SCHEMBL11688571)	0.81	2/20
Paromamine (SCHEMBL2736463)	0.79	2/20
Paromamine (SCHEMBL8812240)	0.79	2/20
Paromamine (SCHEMBL12168155)	0.79	2/20
SCHEMBL12647030	0.77	2/20
SCHEMBL12167988	0.76	2/20

Clinical trials — most relevant to LRAT by text similarity (a relevance ranking, not an exhaustive list)

Trial	Phase	Status
The Low HDL On Six Weeks Statin Therapy (LOW) Study	PHASE4	UNKNOWN
Effect of Virgin Coconut Oil (VCO) on Cardiometabolic Parameters in Patients With Dyslipidemia	PHASE4	COMPLETED
Effect of Silymarin in Rheumatoid Arthritis Patients Treated With Methotrexate	PHASE4	NOT_YET_RECRUITING
Comparative Study Between Obeticholic Acid Versus Vitamin E in Patients with Non-alcoholic Steatohepatitis	PHASE2	ACTIVE_NOT_RECRUITING
Atorvastatin, L-Carnitine and Non-Alcoholic Steatohepatitis	PHASE2	UNKNOWN
Metabolic Cofactor Supplementation in Obese Patients With Non-Alcoholic Fatty Liver Disease	PHASE2	COMPLETED
Safety/Proof of Concept Study of Oral QLT091001 in Subjects With Leber Congenital Amaurosis (LCA) or Retinitis Pigmentosa (RP) Due to Retinal Pigment Epithelial 65 Protein (RPE65) or Lecithin:Retinol Acyltransferase (LRAT) Mutations	PHASE1	COMPLETED
Epidemiology of Atherosclerosis	nan	COMPLETED
Combining Gene Variants to Improve Risk Prediction for Metabolic (Dysfunction)- Associated Fatty Liver Disease and Its Progression to Cirrhosis in Indian Individuals With Type 2 Diabetes	nan	COMPLETED
Intestines and Liver Contribution to Fasting Postprandial Hypertriglyceridemia	nan	COMPLETED
Association Between HDL Functions and Atherosclerotic Burden in Healthy Individuals	nan	COMPLETED
Natural History Study in Inherited Retinal Disease Subjects Caused by Mutations in RPE65 or LRAT	nan	COMPLETED
Evaluation of HDL Subfraction Changes and HDL-Associated Enzymes in Liver Failure Patients and Healthy Donors	nan	COMPLETED
Genetic Epidemiology of Lipoprotein-Lipid Levels	nan	COMPLETED
Evaluation of Botanicals for Mechanisms Related to Appetite and Fat Metabolism	nan	COMPLETED
Development of Biomarker for Development of Non-Alcoholic Steatohepatitis (NASH) in Children	nan	WITHDRAWN
Serum Betatrophin Levels and Its Influencing Factors in Patients With Hyperthyroidism	nan	UNKNOWN
Fish Oil and Nonalcoholic Fatty Liver Disease (NAFLD) Study	nan	COMPLETED
Mechanisms of Inherited Retinal Dystrophies Using Whole Genome Sequencing and in Vitro and in Vivo Models	nan	COMPLETED
Development of a Novel Biomarker for Liver Fibrosis	nan	COMPLETED
Evaluation of Risk of hEpatocellular Carcinoma	nan	RECRUITING
Triglyceride-rich LIPoproteins and INflammatory Cytokines After Oral FAT Loading as Potential Early Biomarkers of the Risk of Progression Towards DIABETES and Development of Complications. LIPINFAT Diabetes Study.	nan	RECRUITING
A 12 Week, 3-Period Study to Evaluate the Effects of a Dietary Supplement on Lipid Metabolism	nan	COMPLETED
Effect of Omega-3 Fatty Acids Supplementation on Hypertriglyceridemia in Pediatric Patients With Obesity.	nan	COMPLETED
Dietary Fat, Plasma Lipids, and Other CHD Risk Factors	nan	COMPLETED
FGF19 in Obstructive Cholestasis: Unveil the Signal	nan	UNKNOWN
Assessment Of Lipid Profile In Cirrhotic Patients	nan	COMPLETED
A Registration Study for Familial Hypercholesterolemia in Taiwan	nan	UNKNOWN
Effects of Colesevelam HCl On Bile Acid Kinetics	nan	COMPLETED
Gene Expression in Obesity and Insulin Resistance	nan	COMPLETED

Related proteins — ESM-2 sequence neighbours (a LRAT binder may also engage these)

Protein	Name	Similarity
Q9BGL2	—	1.000	Q9BGL2 →
Q9JI61	—	0.997	Q9JI61 →
Q9JI60	—	0.996	Q9JI60 →
A0A0R4IY06	—	0.971	A0A0R4IY06 →
A7MBC7	—	0.967	A7MBC7 →
Q93V51	—	0.967	Q93V51 →
O14524	—	0.964	O14524 →
Q6ZQE4	—	0.963	Q6ZQE4 →
F1ND48	—	0.962	F1ND48 →
Q5RDB4	—	0.962	Q5RDB4 →
Q9HDD0	—	0.960	Q9HDD0 →
Q5RED8	—	0.959	Q5RED8 →
MAP3K5	Mitogen-activated protein kinase kinase kinase 5	0.959	landscape →
A0JPF9	—	0.959	A0JPF9 →
X1WEM4	—	0.958	X1WEM4 →
Q502W6	—	0.958	Q502W6 →
O35099	—	0.958	O35099 →
Q9BXT6	—	0.958	Q9BXT6 →
Q4R6Y8	—	0.957	Q4R6Y8 →
B5DE73	—	0.957	B5DE73 →
O94952	—	0.957	O94952 →
Q1RMU2	—	0.957	Q1RMU2 →
Q96QE5	—	0.957	Q96QE5 →
Q8NE18	—	0.956	Q8NE18 →
Q80TQ2	—	0.956	Q80TQ2 →
Q2TBQ7	—	0.956	Q2TBQ7 →
Q5VW38	—	0.956	Q5VW38 →
Q7TPQ3	—	0.956	Q7TPQ3 →
A4IGD2	—	0.956	A4IGD2 →
D2KX21	—	0.956	D2KX21 →